会员体验
专利管家（专利管理）
工作空间（专利管理）
风险监控（情报监控）
数据分析（专利分析）
侵权分析（诉讼无效）
联系我们
交流群
官方交流：
QQ群： 891211   
微信请扫码    >>>
现在联系顾问~
下载
著录项
PDF全文
热词
    • 1. 发明授权
      US08829003B2 Compounds for treating proliferative disorders 有权
    • Compounds for treating proliferative disorders
    • US08829003B2
    • 2014-09-09
    • US13806602
    • 2011-06-21
    • Shudong Wang , Osama Chahrour , Tiangong Lu , Anran Hu
    • Shudong Wang , Osama Chahrour , Tiangong Lu , Anran Hu
    • A61K31/497 , C07D213/62
    • C07D213/74 , C07D213/73 , C07D213/75 , C07D213/76 , C07D239/47 , C07D401/04
    • A compound of formula (I) or a pharmaceutically acceptable salt or solvate or physiologically hydrolysable, solubilizing or immobilizable derivative thereof; wherein: any one or two of X., X2 and X3 is a N atom and the remaining two or one of X1, X2 and X3 are independently CR13; Y is selected from SO2 and SO; R1, R2, R3, and R7 and the one or two R13 groups are each independently selected from H and R10, R10 is selected from R8, alkyl, aryl, heteroaryl and combinations of two or more thereof and combinations with one or more R9, or R10 is one or more moieties R11 Sinking one or more alkyl, alkoxy, aryl, heteroaryl or R8 or R9 groups or combinations thereof, directly or via a moiety selected from alkylene, arylene, heteroarylene or combinations thereof, wherein alkyl, aryl, heteroaryl groups or moieties thereof may be substituted with one or more groups R12, or R10 is selected from a group R12; R11 is selected from 0-, N—, NH—, N═C, CO—, C00-, CON—, CONH—, S02-, S02N—, S02NH—; R12 is selected from halogen, NH2, N02, CN, OH, COOH, CONH2, C(═NH)NH2, S03H, S02NH2, S02CH3, OCH3, OCH2CH3, CF3; R8 and R9 comprise one or more solubilizing moieties independently chosen from i) neutral hydrophilic groups, ii) ionisable organic acids, iii) ionisable organic bases, iv} chemical functions or moieties providing covalent or non-covalent attachment or binding to a solid phase or an immobile receptor and combinations thereof; R4, R5 and R6 are each independently selected from H and R10, or two of R4 to R6 are linked to form a cyclic ether or amine containing one or more additional oxygen or nitrogen atoms. The compound may be used for treating a condition mediated by one or more enzymes selected from AKT, Aurora kinase, BCR-ABL, CDK, FLT, GSK3, IKK, JAK, MAPK, PDGF, PI3K, PKA, PKB, PKC, PLK, Src and VEGF family enzymes, or for treating cancer or other proliferative disorder, or for inhibiting growth of cancer cells, or for inducing apoptosis of cancer cells, in a human or animal subject.
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
    • 2. 发明申请
      US20110092490A1 PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS 审中-公开
    • PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS
    • 吡咯嗪，三氮唑及其作为药物代用品
    • US20110092490A1
    • 2011-04-21
    • US12934798
    • 2009-03-26
    • Shudong Wang , Shenhua Shi , Andrey Zaytsev , Peter Martin Fischer
    • Shudong Wang , Shenhua Shi , Andrey Zaytsev , Peter Martin Fischer
    • A61K31/5377 , C07D417/14 , C07D417/04 , A61K31/506 , A61K31/496 , A61K31/551 , A61P35/00 , A61P35/02 , A61P17/06 , A61P9/00 , A61P3/00 , A61P37/00 , A61P31/00
    • C07D417/04 , C07D251/18
    • A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X1 and X2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N, Se; Z is NH, NHCO, NHSO2, N-alkyl, CH2NH, CH2N-alkyl, CH2, CH2CH2, CH═CH, CH2CONH, SO2, or SO; Y is N CR3; R1, R2, R5, R6, R7, R8 and R9 are each independently H, or a substituent; R3, when present, is selected from alkyl and a substituent, with the proviso that when Y is CR3, Ar is a 5-membered heterocycle comprising one or two N heteroatoms and Z is NH, then R3 is selected from C3+ alkyl and a substituent; R4 is selected from H, alkyl and R13 as hereinbefore defined, with the proviso that when R3 is absent, R4 is selected from alkyl and a substituent; processes for the preparation thereof, intermediates and precursors therefore and the use thereof as a medicament, and therapeutic compositions comprising the compound.
    • 式（I）化合物及其药学上可接受的盐或溶剂化物和生理上可水解，增溶或可固化的衍生物，其中：Ar是5元杂芳基环，其中X 1和X 2是一个或两个杂原子或Ar是6-元芳环 其中杂原子选自S，O，N，Se; Z是NH，NHCO，NHSO 2，N-烷基，CH 2 NH，CH 2 N-烷基，CH 2，CH 2 CH 2，CH = CH，CH 2 CONH，SO 2或SO; Y是N CR3; R1，R2，R5，R6，R7，R8和R9各自独立地为H或取代基; 当存在时，R3选自烷基和取代基，条件是当Y为CR 3时，Ar为包含一个或两个N个杂原子且Z为NH的5元杂环，则R3选自C3 +烷基和取代基 ; R 4选自如上文所定义的H，烷基和R 13，条件是当R 3不存在时，R 4选自烷基和取代基; 因此，其制备方法，中间体和前体及其作为药物的用途，以及包含该化合物的治疗组合物。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 7. 发明申请
      US20120003132A1 Process for catalytic deoxygenation of coal mine methane 审中-公开
    • Process for catalytic deoxygenation of coal mine methane
    • 煤矿瓦斯催化脱氧工艺
    • US20120003132A1
    • 2012-01-05
    • US12737342
    • 2010-04-19
    • Shudong Wang , Sheng Wang , Zhongshan Yuan , Chunxi Zhang , Changjun Ni , Deyi Li
    • Shudong Wang , Sheng Wang , Zhongshan Yuan , Chunxi Zhang , Changjun Ni , Deyi Li
    • B01D53/46 , B01J29/068 , B01J21/16 , B01J23/63
    • B01J23/63 , B01J21/066 , B01J23/002 , B01J23/58 , B01J37/0242 , B01J2523/00 , C10L3/101 , B01J2523/3712 , B01J2523/48 , B01J2523/3737 , B01J2523/31
    • Deoxygenation catalyst for coal mine methane, its preparation method and application in catalytic deoxygenation of coal mine methane in oxygen-containing environment. The catalyst comprises a first composition serving as the active content and a second composition serving as the additive. The first composition consists of one or more platinum group noble metals selecting from the group consisting of Pd, Pt, Ru, Rh and Ir. The second composition consists of one or more alkaline metals or alkaline earth metals selected from the group consisting of Na2O, K2O, MgO, CaO, SrO and BaO; CeO2 and lanthanides rare earth metals such as Pr, Nd, Sm, Eu, Gd, etc.; and/or transition metals such as Y, Zr, La, etc.; and/or Al2O3 oxides complexes. Said catalyst can effectively eliminate the oscillatory behavior during catalytic combustion under oxyen-lean condition. When said catalyst is applied in the catalytic deoxygenation process of the present invention, 1 to 15% of oxygen in coal mine methane can be effectively removed and a percentage yield of methane which approximately equals to the theoretical percentage yield obtained under the assumption of complete conversion of methane and oxygen can be achieved.
    • 煤矿瓦斯脱氧催化剂及其在含氧环境中煤矿瓦斯催化脱氧的制备方法及应用。 催化剂包含作为活性成分的第一组合物和作为添加剂的第二组合物。 第一组合物由选自Pd，Pt，Ru，Rh和Ir的一种或多种铂族贵金属组成。 第二组合物由选自Na2O，K2O，MgO，CaO，SrO和BaO的一种或多种碱金属或碱土金属组成。 CeO2和镧系稀土金属如Pr，Nd，Sm，Eu，Gd等; 和/或过渡金属如Y，Zr，La等; 和/或Al 2 O 3氧化物络合物。 所述催化剂可以有效地消除贫氧条件下催化燃烧过程中的振荡行为。 当在本发明的催化脱氧方法中使用所述催化剂时，可以有效地除去煤矿甲烷中的1〜15％的氧气，甲烷的产率几乎等于在完全转化的情况下获得的理论百分比产率 的甲烷和氧气可以实现。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
每页展示10个专利
每页展示10个专利
每页展示20个专利
每页展示50个专利
每页展示100个专利

IPRDB

最新中国发明专利 最新美国发明专利 技术领域 专利库 专利分类库 国际专利分类库

热门服务

会员版试用 API 数据接口 找代理 知嘟嘟专利交易 排行榜 大学排行榜 专利百科

关于我们

平台介绍 战略合作 网站地图

友情链接

知嘟嘟专利交易 国家知识产权局 中国商标网

联系方式


©2019-2023 上海吉码数字技术有限公司 版权所有，并保留所有权利 沪ICP备20016256号-6 沪公网安备31011702005475号